title: Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients.
abstract: BACKGROUND
  Seasonal allergic rhinoconjunctivitis (SARC) affects ≥16% of the US population annually. Telephone and in-office surveys have demonstrated negative effects of allergic rhinitis (AR) symptoms on sleep, daily activities, productivity, concentration, and emotions.
  
  
  OBJECTIVE
  The objective of this study was to assess the patient-perceived burden of SARC in relation to newer treatments, increased access to treatments, and changing management protocols.
  
  
  METHODS
  An online survey of symptom experience, impact on daily life, and management was conducted in US respondents who suffer (or whose child suffers) from SARC symptoms.
  
  
  RESULTS
  A total of 1001 surveys were completed: 500 adults (≥18 years old) and 501 children (12-17 years old, documented by their parents). Similar to earlier AR surveys, SARC symptoms negatively affected the patient's (and family's) quality of life, and were most severe in the spring. Before being treated, >50% of respondents reported daily symptoms during their season; 75% to 80% considered their symptoms moderate to severe. Patients saw a variety of health care professionals (including pharmacists) and used over-the-counter and prescription medications for symptoms. Those using prescription medications were generally more satisfied with treatment and less likely to switch or discontinue treatment. Nasal and/or ocular symptoms drove adherence, seeing a health care professional, and reviewing and/or changing treatment.
  
  
  CONCLUSIONS
  The majority of patients with SARC report moderate-to-severe symptoms that significantly impair their quality of life. However, patients appear to be taking more responsibility for their (child's) condition, and patient expectations for therapy are increasingly being met. Continued efforts will be needed to examine the contribution of better information and/or increased access to and availability of medications to control the disease.
authors.affiliation: Division of Immunology and Allergy, Department of Pediatrics, University of California San Diego School of Medicine, and Allergy and Asthma Medical Group and Research Center, San Diego, Calif. Electronic address: eliomeltzer@gmail.com.
authors.forename: Eli O
authors.initials: EO
authors.lastname: Meltzer
authors.affiliation: Academic Services Connection, Inc., Canandaigua, NY.
authors.forename: Judith Rosen
authors.initials: JR
authors.lastname: Farrar
authors.affiliation: Asthma and Allergy Foundation of America, Landover, Md.
authors.forename: Cary
authors.initials: C
authors.lastname: Sennett
mesh_terms: D000293:Adolescent; D002648:Child; D003233:Conjunctivitis, Allergic / Q000453:epidemiology* / Q000628:therapy; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D008297:Male; D055118:Medication Adherence; D011788:Quality of Life; D006255:Rhinitis, Allergic, Seasonal / Q000453:epidemiology* / Q000628:therapy*; D011795:Surveys and Questionnaires; D014481:United States / Q000453:epidemiology
keywords: Allergic rhinitis; Antiallergic treatment; Nasal/ocular allergy symptoms; Patient perception; Quality of life; Questionnaire; Seasonal allergic rhinoconjunctivitis; Survey